Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT)

Michael Makris MD1,2 | Sue Pavord MD3 | William Lester MD4 | Marie Scully MD5 | Beverley Hunt MD6

1Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
2Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
3Department of Haematology, Oxford University Hospitals, Oxford, UK
4Department of Haematology, University Hospitals Birmingham and Institute of Cardiovascular Sciences, Birmingham, UK
5Department of Haematology, University College London Hospitals NHS Foundation Trust and Cardiometabolic Programme-NIHR UCLH/UC BRC London, London, UK
6Centre for Thrombosis and Haemophilia, Guy's and St Thomas' NHS Foundation Trust, London, UK

Correspondence: Michael Makris, Department of Haematology, Royal Hallamshire Hospital, Glossop Road, Sheffield, S10 2JF, UK.
Email: m.makris@sheffield.ac.uk

Keywords: COVID-19, thrombocytopenia, thrombosis, vaccine, VITT

The coronavirus disease 2019 (COVID-19) pandemic has affected every part of the world, causing major morbidity and mortality as well as impacting heavily on the economy of every nation. As for other infectious diseases, vaccination is seen as the primary way to control the infection. A number of vaccines against COVID-19 have now been approved internationally. The AstraZeneca Oxford (AZ) COVID-19 vaccine was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK regulator, on December 30, 2020, and by the European Medicines Agency (EMA), the European regulator, on January 29, 2021. This is one of the most widely used COVID-19 vaccines worldwide.

Concerns about a high number of unusual thrombotic events following vaccination with the AZ vaccine started to grow in early March 2021. On March 11, 2021, both the MHRA and the EMA provided reassurance that the number of events observed was no higher than expected and advised the continued use of this vaccine as the benefits outweighed the risks.1,2 Within a week, however, researchers from Norway, Germany, and the United Kingdom reported on a group of patients who had been previously healthy but were admitted within 3 weeks of AZ vaccination with an unusual combination of cerebral venous sinus thrombosis (CVST) and thrombocytopenia. All three groups independently identified that their patients had circulating antibodies against platelet factor 4 (PF4), which were detected using the heparin-induced thrombocytopenia (HIT) ELISA assay.

Schultz and colleagues3 from Norway reported on five patients admitted to the hospital with thrombosis (four CVST, one portal vein) and thrombocytopenia 7 to 10 days after AZ vaccination. In Norway, health care personnel younger than 65 years were selected to receive the AZ vaccine first, and the five cases appeared after 132 686 first doses of the vaccine were administered. Three of the women were on hormonal therapy. All five patients had high levels of IgG against PF4-polyanion complexes and also had platelet activation detected with a functional assay.3

Greinacher and colleagues4 from Germany and Austria reported on 11 patients who presented 5 to 16 days after AZ vaccination with multiple thromboses and thrombocytopenia. Nine of the patients had CVST, three had splanchnic vein thrombosis, three had pulmonary embolism, and other types of thrombosis were detected in four patients. In one patient who died from cerebral bleeding, CVST could not be excluded. Using an ELISA assay, the authors showed that the patients had circulating antibodies against PF4-heparin and...
also that there was platelet activation which could be inhibited by immune globulin providing support for a proposed treatment for this condition.4

In a report of the early UK experience, Scully and colleagues5 described 23 patients presenting 6 to 24 days after AZ vaccination with thrombosis and thrombocytopenia. CVST was the most common type of thrombosis, with many patients presenting with thrombosis in several locations. Although the thrombotic events were primarily venous, two patients had ischemic strokes in the middle cerebral artery territory, one had a myocardial infarction, and one had an aortic thrombus. Patients were positive for anti-PF4 antibodies on two HIT ELISA tests, findings that were confirmed using a functional assay. A case of thrombocytopenia from a typical postvaccine immune thrombocytopenia.5 Although equivalent laboratory findings to those with thrombosis, distinguishing the syndrome was termed heparin-induced thrombocytopenia (HIT).6-8 It was noted more than 10 years ago that a condition similar to HIT could rarely occur without heparin exposure, and the condition was termed spontaneous9 or autoimmune HIT.10 It remained extremely rare, or at least it was recognized extremely rarely.10 These patients developed anti-PF4 antibodies without exposure to heparin.

So far, VITT has been reported only after the AZ and J&J COVID-19 vaccines, which are based on replication-incompetent adenoviral vectors (Chimpanzee ChAdOx1 for AZ and Human Ad26, COV2.S for J&J). It is likely that an anionic molecule present in the vaccine or produced by the cells at the vaccination site binds to PF4 (a cationic molecule), inducing antibody formation. As with HIT, these antibodies bind to platelets via the Fc gamma RIIA receptors leading to platelet activation. At the time of writing, it remains unclear which component of the vaccine is responsible for causing the production of anti-PF4 antibodies; it could be the adenovirus itself, the spike protein cassette, or other constituents of the vaccine such as polysorbate 80. Furthermore, it is not clear whether this constituent acts as a hapten or whether it is due to molecular mimicry (sequence homology between PF4 and a part of the spike protein).

Patients with VITT are typically admitted to the hospital 5 to 24 (median, 10-12) days after AZ or J&J vaccination with atypical (unusual site) thrombosis and thrombocytopenia (Table 2). The majority of thrombotic events reported so far have been CVST or portal vein thrombosis. More typical venous thrombotic events such as deep vein thrombosis or pulmonary embolism have also been reported. Arterial events such as bilateral leg ischemia, myocardial infarction, or stroke constitute at least 10% of acute admissions. Overall age of presentation is <60 years, and although in the reports from Norway

| Reference | Vaccine | Country/Area | Number | Age, y, mean (range) | Sex | Primary thrombosis type | Platelet count, ×10^9/L, mean (range) | Outcome |
|-----------|---------|--------------|--------|---------------------|-----|------------------------|--------------------------------------|---------|
| Schultz et al3 | AZ | Norway | 5 | 40.8 (32-54) | 4 F, 1 M | 4 CVST 1 portal vein | 27 (10-70) | Fatal 60% |
| Greinacher et al4 | AZ | Germany and Austria | 11 | 36 (22-49) | 9 F, 2 M | 9 CVST 1 PE | 35 (8-107) | Fatal 55% |
| Scully et al5 | AZ | United Kingdom | 23 | 46 (21-77) | 13 F, 10 M | 13 CVST 4 PE 1 DVT 2 MCA strokes 2 portal vein | 44 (7-113) | Fatal 30% |
| Muir et al6 | J&J | United States | 1 | 48 | 1 F | 1 CVST | 13 | Critically ill at reporting |

Abbreviations: AZ, AstraZeneca; CVST, cerebral venous sinus thrombosis; DVT, deep vein thrombosis; F, female; J&J, Johnson & Johnson; M, male; MCA, middle cerebral artery territory; PE, pulmonary embolism.
and Germany it was mostly women, in the United Kingdom we are seeing a more equal sex distribution. One possible reason for this variation is the different national rollout schedules, which in Norway and Germany concentrated on health care workers, where there is a female excess. A further striking similarity between the current published cases is the significant mortality, ranging from 30% to 60% (Table 1). The platelet count tends to be lower than that seen with HIT, and there is often a reduction in fibrinogen and a marked elevation in the D-dimer levels. Patients have strongly positive anti-PF4-polyanion or anti-PF4-heparin antibodies detected by the HIT ELISA, but the HIT chemiluminescence assays are often negative. This most likely reflects the different specificities of the assays to heparin itself.

The management of patients is extrapolated from the treatment of autoimmune HIT, consisting of avoiding platelet transfusions and heparin exposure and using intravenous immunoglobulin (IVIG).12 Our UK experience is that it is important to give high-dose IVIG early to turn off the prothrombotic process. Given the similarities to HIT, anti-coagulation is currently provided through nonheparin anticoagulants such as argatroban, fondaparinux, or DOAC. Anticoagulation is more challenging in patients with marked thrombocytopenia such as those with platelet counts <30 × 10^9/L since severe bleeding into the brain is more common than with non-vaccination-related CVST or with HIT. In many of the patients who died with VITT, the cause of death was intracerebral hemorrhage. Intervention in very extensive CVST with thrombectomy and/or neurosurgery should be considered, and an early discussion with neurosurgery is advised. Transfusion to correct hypofibrinogenemia and thrombocytopenia are recommended before invasive procedures. Uncertainties remain, such as the value of steroids, whether heparin can be used safely in all cases and the benefits versus risks of prophylactic platelet transfusion other than for surgery.

It is important to appreciate that it is <6 weeks since the possibility of an unusual thrombotic pattern after the AZ vaccination was considered. We are bound to learn more in the next few weeks or months, including the true incidence, the optimal management, and, importantly, the length of time the antibodies persist as well as whether or not antibody persistence will be associated with recurrence of VITT. In particular, we do not know the natural history of the antibody in terms of persistence and expression of disease. We are concerned that it may persist for months and we may need to give repeated treatment for thrombocytopenia. Thus, any patients who present with this condition need close follow-up, with measurement of anti-PF4 antibodies and routine laboratory parameters, such as platelet count and D-dimer and fibrinogen levels.

**RELATIONSHIP DISCLOSURE**

The authors declare no conflicts of interest.

**AUTHOR CONTRIBUTIONS**

All authors contributed equally to this article.

**ORCID**

Michael Makris https://orcid.org/0000-0001-7622-7939

Beverley Hunt https://orcid.org/0000-0002-4709-0774

**REFERENCES**

1. https://www.gov.uk/government/news/mhra-response-to-danish-authorities-action-to-temporarily-suspend-the-astraZeneca-covid-19-vaccine (accessed 20 April 2021).
2. https://www.ema.europa.eu/en/news/covid-19-vaccine-astraZeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits (accessed 20 April 2021).
3. Schultz NH, Sorvoll IH, Michelsen AE et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021. (in press).
4. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021. (in press).
5. Scully M, Singh D, Lown R et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19. *N Engl J Med*. 2021. (in press).
6. Muir KL, Kalam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. *N Engl J Med*. 2021. (in press)
7. Greinacher A. Heparin induced thrombocytopenia. *N Engl J Med*. 2015;373:252-261.
8. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. *Br J Haematol*. 2012;159:528-540.
9. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. *Am J Med*. 2008;121:652-656.
10. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. *J Thromb Haemost*. 2017;15:2099-2114.
11. Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12:685-698.

12. Lee SK, Mokin M, Hetts SW, Fifi JT, Bousser MG, Fraser JF. Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee. J Neurointerv Surg. 2018;10:803-810.

How to cite this article: Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). Res Pract Thromb Haemost. 2021;5:e12529. https://doi.org/10.1002/rth2.12529